PHC Holdings Corporation, a subsidiary of PHC Corporation (Headquarters: Minato-ku, Tokyo; President: Shinro Nakamura; hereinafter referred to as "PHC ) and Cyfuse Co., Ltd. (Headquarters: Minato-ku, Tokyo; Representative Director: Shizuka Akieda; hereinafter “Cyfuse”) have signed a basic agreement on a business alliance with the aim of strengthening their strategic partnership.

In the future, using the technologies and know-how of both companies, we will promote joint development, etc. with an eye on commercialization and industrialization in the field of regenerative medicine and cell therapy (hereinafter referred to as "this field"), and Cyfuse will develop innovative regenerative medicine. We will accelerate the commercialization of such products.

PHC is a global healthcare company that develops, manufactures, sells and services in the diabetes management, diagnostics and life sciences business areas. For more than 30 years, the company's diagnostic reagents division has developed and manufactured high-performance medical devices, including blood glucose measurement systems, to support effective treatment of patients.

Cyfuse utilizes its unique base technology called bio 3D printing, which enables various three-dimensional models using only cells, and is launching innovative regenerative medicine products for use in regenerative medicine such as nerve regeneration, bone cartilage regeneration, and blood vessel regeneration. We are proceeding with clinical development for practical application as an alternative treatment option.

In this field, which is expected to expand further in the future, the two companies will utilize the original traceability system accumulated in the development and production process of PHC's blood glucose measurement system to create a high-quality production environment and rational production. We will establish management, etc., and work to build a production system for the commercialization of Cyfuse's innovative regenerative medicine products.

Through the strengthening of the alliance between the two companies, we will expand the value chain, promote various R&D and technological development, including Cyfuse's innovative regenerative medicine products, and create new products. We expect to contribute to growth and development.

In the future, Cyfuse's proprietary bio 3D printing basic technology will be combined with the precision and highly reliable manufacturing capabilities of PHC, a global healthcare company, to create new markets and industries from Japan to the world. Aim for development.

Hiroyuki Tokunaga, Director and General Manager of Diagnostics Division at PHC, said:

“I am delighted to be able to work with Cyfuse for the practical application of regenerative medicine and cell therapy. By combining the technologies and know-how of PHC and Cyfuse, we will be able to create new value for patients and advanced medical settings. Along with proposing the We look forward to helping you expand your options.”

Chikahiko Tokunaga, Director and General Manager of Systems Development at Cyfuse, said:

“We are very pleased to be able to further strengthen our partnership with the PHC Group, which is active globally in the healthcare field, and to work together for industrialization. Building a production system in the field of cell therapy and cultivating new markets together. Further development of the new industrial field of regenerative medicine and cell therapy, including the commercialization of Cyfuse's regenerative medicine products.

 

Source: businesswire.com
 

Report Abuse